Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;138(2):179-87.
doi: 10.1007/s00432-011-1072-3. Epub 2011 Oct 5.

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials

Fausto Petrelli  1 , Karen Borgonovo, Mary Cabiddu, Veronica Lonati, Sandro Barni
Affiliations
Review

Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials

Fausto Petrelli et al. J Cancer Res Clin Oncol. 2012 Feb.

Abstract

Background: Iron supplementation could improve the hematopoietic response of erythropoiesis-stimulating agents (ESAs) used for chemotherapy-induced anemia.

Methods: We performed a meta-analysis of randomized, controlled trials by comparing parenteral or oral iron and no iron, when added to ESAs in anemic cancer patients, in order to calculate the relative risk (RR) of hematopoietic response and transfusions, the time required to reach this response, and toxicity.

Results: A total of 1,606 patients out of eight trials were available for meta-analysis. The RR of obtaining an hematopoietic response was 1.29 (P = 0.0001) with parenteral iron and 1.04 for oral iron (P = 0.59). The risk of transfusion was reduced with parenteral iron versus no iron (RR 0.77; P = 0.02) but not with oral iron (RR 0.68; P = 0.08). The time to reach hematopoietic response was 1 month shorter and no increased toxicity appeared with iron supplementation.

Conclusion: Overall parenteral iron reduces the risk of transfusions by 23% and increases the chance of hematopoietic response by 29% when compared with ESAs alone. On the contrary, oral iron does not increase hematopoietic response nor transfusion rate. The significance of these results is that the proportion of non-responders to ESAs will have strongly improved and quality of life and cost ameliorated.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Funnel plot for hematopoietic response (primary endpoint; eight trials)
Fig. 2
Fig. 2
Flow diagram of the study selection process
Fig. 3
Fig. 3
Forest plot for RR of obtaining an hematopoietic response with parenteral iron
Fig. 4
Fig. 4
Forest plot for RR of transfusion with parenteral iron
Fig. 5
Fig. 5
Forest plot for RR of transfusion with oral iron
See this image and copyright information in PMC

Comment in

References

    1. Auerbach M, Ballard H, Trout JR et al (2004) Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 22(7):1301–1307 - DOI - PubMed
    1. Auerbach M, Silberstein PT, Webb RT et al (2010) Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. Am J Hematol 85(9):655–663 - DOI - PubMed
    1. Bastit L, Vandebroek A, Altintas S et al (2008) Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 26(10):1611–1618 - DOI - PubMed
    1. Demetri GD, Kris M, Wade J et al (1998) Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412–3425 - PubMed
    1. Gabrilove JL, Cleeland CS, Livingston RB et al (2001) Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 19:2875–2882 - PubMed

MeSH terms

LinkOut - more resources